Identifying Disease-Related Variants, Monogenic Disorders, and Repeat Expansion Disorders

Identification of Disease-Related Genetic Variants


GWAS vs WGS
  • Genome-Wide Approaches:

    • Genome-Wide Association Studies (GWASGWAS): Compares allele frequencies in large case-control cohorts using SNPSNP microarrays to identify common susceptibility variants (SNPs\text{SNPs}). Requires functional biological validation.

    • Whole Genome Sequencing (WGSWGS): Direct determination of an individual's complete genome sequence to identify single-nucleotide variants (SNVsSNVs), insertions/deletions (indelsindels), copy number variants (CNVsCNVs), and structural variants (SVsSVs). Main bottleneck is variant filtering and prioritization.

  • Human Genome Variation Overview:

    

Types of Genetic Variation


  • Non-variable Portion: Comprises ∼99.6% of the diploid genome (∼5,973,000,000 base pairs).

  • Single-Nucleotide Variants (SNVs): Most common by count (∼5,000,000 per genome; ∼0.08% base coverage).

  • Insertions and Deletions (Indels): ∼600,000 variants per genome (∼0.03% base coverage).

  • Structural Variants (SVs / CNVs): Least common by count (∼25,000 per genome), but affect the greatest total base coverage (>20,000,000 nucleotides).


Monogenic Disorders and Case Study: Cystic Fibrosis

  • Monogenic Disorders: Caused by pathogenic variants in a single locus. Can be inherited or de novo, with variable penetrance, severity, and age of onset.

  • Cystic Fibrosis (CFCF):

    

CFTR Channel Function


  • Inheritance & Gene: Autosomal recessive disorder caused by loss-of-function variants in both alleles of CFTR (encodes an ATP-binding cassette Cl− and HCO3−​ ion channel on apical membranes).

  • Pathophysiology: Loss of transport creates an osmotic deficit, causing abnormally thick mucus obstructing airways, pancreatic ducts, and other epithelia. Symptoms include recurrent lung infections, exocrine pancreatic insufficiency, failure to thrive, and elevated sweat chloride.

  • Most Common Variant (F508del / c.1521_1523delCTT): Accounts for ∼66.8% of alleles worldwide. In-frame deletion of phenylalanine at position 508 causes protein misfolding, endoplasmic reticulum retention, and proteasomal degradation.    


F508del Variant
- **Functional Classes**:

        

CFTR Mutation Classes

- **Class I**: No protein synthesis (e.g., G542XG542X).

- **Class II**: Block in processing/maturation & proteasomal degradation (e.g., F508delF508del).

- **Class III**: Block in gating/regulation (e.g., G551DG551D).

- **Class IV**: Reduced channel conductance (e.g., R117HR117H).

- **Class V**: Reduced synthesis (e.g., 3849+10kbC→T3849+10\text{kb}C\rightarrow T).

- **Class VI**: Accelerated turnover / membrane instability (e.g., 4326delTC4326delTC).


Diagnostic Testing for Cystic Fibrosis


Diagnostic Pathway Workflow
  • New Zealand Newborn Screening (NBSNBS):

    • Tier 1: Immunoreactive Trypsinogen (IRTIRT) from bloodspot. Top 1%1\% proceeds to Tier 2.

    • Tier 2: Targeted CFTRCFTR mutation panel covering exon 10/11 variants (F508delF508del, G551DG551D, G542XG542X).

  • Diagnostic Sweat Chloride Thresholds:

    • <30 mmol/L<30\,mmol/L: Unlikely CFCF (if 1 variant found: carrier).

    • 30–59 mmol/L30\text{--}59\,mmol/L: Inconclusive (CFSPIDCFSPID if 2 variants present with unclear consequences).

    • ≥60 mmol/L\ge 60\,mmol/L: Confirms CFCF (requires two variants in trans).

  • Molecular Testing Methods:

    

ARMS-PCR Principle

- **ARMS−PCRARMS-PCR**: Allele-specific PCRPCR using 3′3' terminal matching for targeted known variants.

- **Targeted NGSNGS**: Detects SNVsSNVs, small indelsindels, and splice variants; ineffective for large CNVsCNVs or deep intronic regions.

    

MLPA Principle

- **MLPAMLPA**: Detects single/multi-exon deletions and duplications (CNVsCNVs). Normalized ratio ≈1.0\approx 1.0 (normal), 0.50.5 (heterozygous deletion), 1.51.5 (heterozygous duplication), 0.00.0 (homozygous deletion).

Testing Strategies Across Monogenic Disorders


Testing Strategies Table
  • Familial Hypercholesterolemia (FHFH): LDLRLDLR, APOBAPOB, PCSK9PCSK9 — Targeted NGSNGS panel + MLPAMLPA.

  • Autosomal Dominant Polycystic Kidney Disease (ADPKDADPKD): PKD1PKD1, PKD2PKD2 — Specialised NGSNGS panel with custom long-range PCRPCR / capture + deletion/duplication analysis.

  • Neurofibromatosis Type 1 (NF1NF1): NF1NF1 — Sequencing + MLPAMLPA.

  • Sickle Cell Disease (SCDSCD): HBBHBB (c.20A>Tc.20A>T, p.Glu6Valp.Glu6Val) — Targeted allele-specific genotyping or Sanger/NGSNGS sequencing.

  • Tay-Sachs Disease: HEXAHEXA — Enzyme activity assay followed by targeted sequencing.

  • Phenylketonuria (PKUPKU): PAHPAH — Biochemical newborn screening (MS/MSMS/MS) followed by PAHPAH sequencing.

  • Duchenne Muscular Dystrophy (DMDDMD): DMDDMD — MLPAMLPA first (large exon deletions/duplications), then sequencing if negative.

Repeat Expansion Disorders & Huntington Disease


Types of Tandem Repeats
  • Tandem DNA Repeats:

    • Satellite DNA: Hundreds of kb to Mb arrays in centromeres/heterochromatin.

    • Minisatellites (VNTRsVNTRs): 10–100 bp10\text{--}100\,bp repeat units.

    • Microsatellites (STRsSTRs): 1–6 bp1\text{--}6\,bp repeat units. Expansions beyond thresholds cause disease.

  • Mechanisms of Expansion:

    

Replication Slippage Mechanism
- **Unequal Crossing-Over**: Misalignment during meiotic recombination.

- **Replication Slippage**: Polymerase pausing and hairpin/loop formation during DNA synthesis.
  • Genetic Anticipation: Increase in severity or decrease in age-of-onset in successive generations due to meiotic repeat instability.

  • Huntington Disease (HDHD):

    • Genetics & Pathophysiology: Autosomal dominant expansion of CAG\text{CAG} repeat in Exon 1 of HTTHTT (4p16.34p16.3), producing an N-terminal polyglutamine (polyQ\text{polyQ}) tract that misfolds, aggregates, and causes striatal neurodegeneration.

    

HTT CAG Repeat Thresholds
Repeat Thresholds:

    - </= 26: Normal.

    - 27-35: Intermediate (unaffected, unstable in transmission).

    - 36-39: Reduced penetrance.

    - >/=40: Fully penetrant.

- Laboratory Diagnosis: Flanking PCR followed by capillary electrophoresis fragment analysis.

Comparative Trinucleotide Repeat Disorders


  • Huntington Disease (HTTHTT): CAG\text{CAG} in coding region →\rightarrow polyQ misfolding & toxic gain-of-function.

  • Fragile X Syndrome (FMR1FMR1): CGG\text{CGG} in 5′ UTR5'\text{ UTR} →\rightarrow hypermethylation and gene silencing.

  • Myotonic Dystrophy Type 1 (DMPKDMPK): CTG\text{CTG} in 3′ UTR3'\text{ UTR} →\rightarrow toxic RNA foci and splicing factor sequestration.

  • Friedreich Ataxia (FXNFXN): GAA\text{GAA} in Intron 1 →\rightarrow heterochromatin formation and frataxin deficiency.